Expert view: Reviewing the biggest innovations in antibody screening
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
List view / Grid view
Articles
Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Expert view: Preparing drug discovery for smart screening era
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Regenerative medicine: enhance cell bioprocessing through cell-based combinatorial culture
Regenerative medicine has emerged as one of the major areas of modern medical therapy. Its primary objective is to restore or establish normal function through the regeneration or replacement of diseased cells, tissues or entire organs. There are a variety of methods and approaches by which this can be achieved.…
Expert view: High-throughput binding kinetic analysis – is it the new frontier in drug discovery?
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
Expert view: Improving R&D productivity with novel screening approaches
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
Expert view: Discovering neuronal cell types
Target the genes that matter for efficient sequencing and analysis with custom-targeted gene panels.
Supporting the progression of phenotypic hits with bioactivity profiling
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
Screening In-Depth Focus 2018
This In-Depth Focus reviews the history of cancer treatments, looks at improving the translation of disease biology though phenomics, and considers how to enhance cell bioprocessing through cell-based combinatorial culture.
Imaging In-Depth Focus 2018
In this issue the latest applications of molecular imaging in drug development are reviewed by Ben Burke and Steve Archibald and new horizons in 3D microscopy are explored by Dimitri Scholz and Karl Gaff.
Stem Cells In-Depth Focus 2018
In this issue: urine-derived stem cells offer an innovative platform for drug testing and disease modelling, a paradigm shift in translational stem cell research, and the role of biomaterials in stem cell-based regenerative medicine.
Drug Target Review – Issue #2 2018
In this issue: the positive impact of genomics on drug discovery, development and deployment, the confluence of biology and technology, and Artificial Intelligence: harnessing the potential to drive progress in drug discovery promises much for phenotypic drug discovery
Could fingerprints play a role in drug trials of the future? A forensic scientist’s perspective
Although readers of Drug Target Review may be more focused upstream of clinical trials in the drug discovery pipeline, the efficacy of clinical trials should also be of interest. Millions of pounds invested in drug discovery in the laboratory could easily go to waste if the clinical trials stage is…
The value of automating assays in screening
This article compares and contrasts a commonly used cell viability assay in manual and automated fashion and provides exemplar data from each scenario.
Taking the brakes off the immune system: modelling effects in non-clinical safety studies
This article focuses on how the immune system functions, the challenges that it presents to drug development and why there are such concerns around safety that need to be investigated in pre-clinical studies. Moreover, it covers the role of checkpoint inhibitors as an attractive target for cancer immunotherapy.
